HC Wainwright Lowers Nyxoah (NASDAQ:NYXH) Price Target to $18.00

Nyxoah (NASDAQ:NYXHFree Report) had its price objective cut by HC Wainwright from $22.00 to $18.00 in a report released on Friday morning, Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued reports about the stock. Stifel Nicolaus restated a buy rating and issued a $27.00 price target on shares of Nyxoah in a report on Wednesday, May 15th. Cantor Fitzgerald lowered their price objective on shares of Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a research note on Wednesday, May 15th. Oppenheimer reduced their price target on shares of Nyxoah from $20.00 to $15.00 and set an outperform rating for the company in a report on Wednesday, May 15th. Finally, Piper Sandler increased their price objective on shares of Nyxoah from $15.00 to $20.00 and gave the company an overweight rating in a research note on Wednesday, March 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $19.40.

Check Out Our Latest Research Report on Nyxoah

Nyxoah Stock Performance

Shares of Nyxoah stock traded up $0.17 during trading on Friday, hitting $8.50. The stock had a trading volume of 154,851 shares, compared to its average volume of 36,619. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00. The firm’s fifty day simple moving average is $11.21 and its 200-day simple moving average is $9.21. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.94 and a quick ratio of 3.70.

Nyxoah (NASDAQ:NYXHGet Free Report) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.41). The firm had revenue of $1.96 million during the quarter, compared to analyst estimates of $2.01 million. Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.49%. As a group, equities analysts anticipate that Nyxoah will post -1.66 earnings per share for the current year.

Hedge Funds Weigh In On Nyxoah

An institutional investor recently bought a new position in Nyxoah stock. Iron Triangle Partners LP acquired a new position in shares of Nyxoah S.A. (NASDAQ:NYXHFree Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 253,025 shares of the company’s stock, valued at approximately $3,413,000. Nyxoah comprises about 0.3% of Iron Triangle Partners LP’s investment portfolio, making the stock its 28th biggest position.

Nyxoah Company Profile

(Get Free Report)

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

Featured Articles

Analyst Recommendations for Nyxoah (NASDAQ:NYXH)

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.